| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 9.06▲ | 8.89▲ | 8.75▲ | 8.75▲ | 10.35▼ |
| MA10 | 9.04▲ | 8.66▲ | 8.58▲ | 9.74▼ | 11.98▼ |
| MA20 | 8.89▲ | 8.56▲ | 8.60▲ | 10.93▼ | 16.46▼ |
| MA50 | 8.62▲ | 8.67▲ | 9.31▼ | 13.48▼ | 26.69▼ |
| MA100 | 8.53▲ | 9.48▼ | 10.61▼ | 17.77▼ | 25.52▼ |
| MA200 | 8.59▲ | 10.74▼ | 11.60▼ | 27.01▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.005▲ | 0.094▲ | 0.131▲ | -0.166▼ | -0.363▼ |
| RSI | 72.896▲ | 66.035▲ | 56.709▲ | 33.815▼ | 33.019▼ |
| STOCH | 80.983▲ | 87.442▲ | 51.782 | 7.188▼ | 6.709▼ |
| WILL %R | -12.500▲ | -5.814▲ | -5.814▲ | -81.573▼ | -93.948▼ |
| CCI | 71.047 | 159.118▲ | 200.630▲ | -80.856 | -128.497▼ |
|
Sunday, March 29, 2026 06:20 AM
Market forces rained on the parade of LENZ Therapeutics, Inc. (NASDAQ:LENZ) shareholders today, when the analysts downgraded their forecasts for this year. Revenue and earnings per share (EPS) ...
|
|
Friday, March 27, 2026 03:47 PM
It failed to meet expectations for its final quarter of 2025.
|
|
Friday, March 27, 2026 09:30 AM
LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 31/03/26 | 8.48 | 9.12 | 8.40 | 9.07 | 877,142 |
| 30/03/26 | 8.97 | 9.00 | 8.25 | 8.29 | 1,262,477 |
| 27/03/26 | 8.90 | 9.25 | 8.395 | 8.40 | 1,369,668 |
| 26/03/26 | 8.91 | 9.18 | 8.565 | 8.94 | 2,000,165 |
| 25/03/26 | 9.21 | 9.39 | 8.99 | 9.07 | 1,424,097 |
| 24/03/26 | 10.47 | 10.47 | 8.85 | 9.03 | 3,912,118 |
| 23/03/26 | 10.73 | 11.475 | 10.62 | 11.00 | 1,478,776 |
| 20/03/26 | 11.36 | 11.525 | 10.44 | 10.48 | 1,332,198 |
| 19/03/26 | 11.59 | 11.87 | 11.22 | 11.43 | 680,945 |
| 18/03/26 | 12.51 | 12.70 | 11.624 | 11.72 | 996,100 |
|
|
||||
|
|
||||
|
|